

ACCESSION NUMBER: 2000:790293 HCAPLUS Full-text

DOCUMENT NUMBER: 133:344615

TITLE: ACE-2 inhibiting compounds, their preparation,
pharmaceutical compositions containing them, and
their therapeutic useINVENTOR(S): Acton, Susan L.; Ocain, Timothy D.; Gould,
Alexandra E.; Dales, Natalie A.; Guan, Bing;
Brown, James A.

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066104	A2	20001109	WO 2000-US11550	20000428
			<--	

WO 2000066104 A3 20010628

WO 2000066104 A9 20020829

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2372387	A1	20001109	CA 2000-2372387	20000428
			<--	

EP 1183019	A2	20020306	EP 2000-926478	20000428
			<--	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
PT, IE, SI, LT, LV, FI, RO

TR 200103094	T2	20020321	TR 2001-3094	20000428
			<--	

BR 2000010166	A	20020604	BR 2000-10166	20000428
			<--	

JP 2002543120	T	20021217	JP 2000-614989	20000428
			<--	

NO 2001005274	A	20011228	NO 2001-5274	20011029
			<--	

ZA 2001009378	A	20021114	ZA 2001-9378	20011114
			<--	

PRIORITY APPLN. INFO.:	US 1999-132034P	P	19990430
	<--		

US 1999-171052P	P	19991216
<--		

WO 2000-US11550	W	20000428
<--		


OTHER SOURCE(S): MARPAT 133:344615

ED Entered STN: 10 Nov 2000

AB ACE-2 inhibiting compds. are disclosed. Methods of using the compds. and
pharmaceutical compns. containing the compds. are also claimed. The compds.
of the invention are useful for treating e.g. blood pressure-related diseases.
Compound preparation is described.

IT 305333-20-4P
 (ACE-2 inhibitor preparation, pharmaceutical compns., and therapeutic use)
 RN 305333-20-4 HCAPLUS
 CN L-Leucine, N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-00
 CC 1-8 (Pharmacology)
 Section cross-reference(s): 34, 63
 IT 20197-09-5P 25303-09-7P 26473-47-2P 84023-58-5P 85649-01-0P
 99473-73-1P 104802-07-5P 113231-05-3P 148020-49-9P
 168540-19-0P 172499-65-9P 305331-48-0P 305331-50-4P
 305331-52-6P 305331-54-8P 305331-56-0P 305331-58-2P
 305331-60-6P 305331-62-8P 305331-64-0P 305331-66-2P
 305331-68-4P 305331-70-8P 305331-73-1P 305331-75-3P
 305331-77-5P 305331-79-7P 305331-81-1P 305331-84-4P
 305331-87-7P 305331-90-2P 305331-93-5P 305331-95-7P
 305331-96-8P 305331-98-0P 305332-00-7P 305332-02-9P
 305332-04-1P 305332-06-3P 305332-08-5P 305332-12-1P
 305332-16-5P 305332-20-1P 305332-24-5P 305332-26-7P
 305332-28-9P 305332-31-4P 305332-33-6P 305332-35-8P
 305332-37-0P 305332-39-2P 305332-41-6P 305332-43-8P
 305332-45-0P 305332-47-2P 305332-49-4P 305332-51-8P
 305332-53-0P 305332-55-2P 305332-57-4P 305332-59-6P
 305332-61-0P 305332-63-2P 305332-65-4P 305332-67-6P
 305332-69-8P 305332-71-2P 305332-73-4P 305332-75-6P
 305332-77-8P 305332-79-0P 305332-81-4P 305332-83-6P
 305332-85-8P 305332-87-0P 305332-89-2P 305332-91-6P
 305332-93-8P 305332-95-0P 305332-97-2P 305332-99-4P
 305333-01-1P 305333-02-2P 305333-04-4P 305333-06-6P
 305333-08-8P 305333-10-2P 305333-12-4P 305333-14-6P
 305333-16-8P 305333-18-0P 305333-20-4P 305333-22-6P
 305333-24-8P 305333-26-0P 305333-28-2P 305333-29-3P
 305333-31-7P 305333-33-9P 305333-35-1P 305333-37-3P
 305333-39-5P 305333-41-9P 305333-43-1P 305333-45-3P
 305333-47-5P 305333-51-1P 305333-54-4P 305333-56-6P
 305333-58-8P 305333-61-3P 305333-63-5P 305333-65-7P
 305333-67-9P 305333-72-6P 305333-74-8P 305333-76-0P
 305333-78-2P 305333-80-6P 305333-82-8P 305333-84-0P
 305333-86-2P 305333-88-4P 305333-90-8P 305333-92-0P
 305333-94-2P 305333-96-4P 305333-98-6P 305334-02-5P
 305334-04-7P 305334-07-0P 305334-09-2P 305334-11-6P
 305334-13-8P 305334-19-4P 305334-21-8P 305334-23-0P
 305334-25-2P 305334-27-4P 305334-29-6P 305334-31-0P
 305334-33-2P 305334-35-4P 305334-37-6P 305334-39-8P
 305334-41-2P 305334-43-4P 305334-45-6P 305334-47-8P
 305334-49-0P 305334-51-4P 305334-53-6P 305334-55-8P
 305334-57-0P 305334-59-2P 305334-62-7P 305334-66-1P
 305334-68-3P 305334-70-7P 305334-72-9P 305334-74-1P
 305334-76-3P 305334-78-5P 305334-80-9P 305334-82-1P

305334-84-3P	305334-86-5P	305334-88-7P	305334-90-1P
305334-91-2P	305334-93-4P	305334-95-6P	305334-97-8P
305334-99-0P	305335-01-7P	305335-03-9P	305335-05-1P
305335-07-3P	305335-09-5P	305335-11-9P	305335-13-1P
305335-15-3P	305335-17-5P	305335-19-7P	305335-21-1P
305335-23-3P	305335-25-5P	305335-27-7P	305335-29-9P
305335-31-3P	305335-33-5P	305335-35-7P	305335-37-9P
305335-39-1P	305335-41-5P	305335-43-7P	305335-45-9P
305335-47-1P	305335-49-3P	305335-51-7P	305335-53-9P
305335-55-1P	305335-57-3P	305335-59-5P	305335-61-9P
305335-63-1P	305335-65-3P	305335-67-5P	305335-69-7P
305335-71-1P	305335-73-3P	305335-75-5P	305335-77-7P
305335-79-9P	305335-81-3P	305335-83-5P	305335-85-7P
305335-87-9P	305335-89-1P	305335-91-5P	305335-93-7P
305335-95-9P	305335-97-1P	305335-99-3P	305336-01-0P
305336-03-2P	305336-05-4P	305336-07-6P	305336-09-8P
305336-11-2P	305336-13-4P	305336-15-6P	305336-17-8P
305336-19-0P	305336-21-4P	305336-23-6P	305336-25-8P
305336-27-0P	305336-29-2P	305336-31-6P	

(ACE-2 inhibitor preparation, pharmaceutical compns., and therapeutic use)